Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
328 studies found for:    Neurotoxicity
Show Display Options
Rank Status Study
1 Recruiting Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer
Condition: Neurotoxicity
Interventions: Drug: placebo;   Drug: GM;   Drug: oxaliplatin-based chemotherapy
2 Recruiting Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients
Condition: Neurotoxicity
Intervention: Drug: monosialoganglioside
3 Terminated A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity
Condition: Neurotoxicity Syndromes
Intervention: Drug: Dextromethorphan
4 Recruiting Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Monosialoganglioside(GM1);   Drug: normal saline
5 Terminated Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through Vitamin D Pathway
Condition: Neurotoxicity
Intervention: Drug: Vitamin D3
6 Completed
Has Results
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
Conditions: Colorectal Cancer;   Neurotoxicity
Interventions: Drug: calcium gluconate;   Drug: magnesium sulfate;   Other: placebo
7 Recruiting Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC
Condition: Colorectal Cancer
Interventions: Drug: monosialotetrahexosylganglioside Sodium;   Other: placebo
8 Recruiting Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: monosialotetrahexosylganglioside Sodium;   Other: placebo
9 Recruiting Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer
Condition: Breast Cancer
Interventions: Drug: EC-T or TC plus GM1;   Drug: EC-T or TC plus placebo
10 Completed Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel 80 mg/m2;   Drug: Nab-paclitaxel 100 mg/m2 days 1, 8 and 15;   Drug: Nab-paclitaxel 150 mg/m2 days 1, 8 and 15;   Drug: Nab-paclitaxel 150 mg/m2 days 1 and 15
11 Completed Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity
Conditions: Neurotoxic Disorders;   Cancer
Intervention: Drug: Mangafodipir
12 Unknown  Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
Condition: Cancer
Interventions: Drug: oxaliplatin;   Procedure: management of therapy complications
13 Unknown  Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
Conditions: Chemotherapeutic Agent Toxicity;   Colorectal Cancer;   Neurotoxicity
Interventions: Drug: FOLFOX regimen;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
14 Recruiting Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer
Conditions: Colorectal Cancer;   Chemotherapy-induced Neutropenia
Interventions: Drug: GM1;   Drug: placebo;   Drug: mFOLFOX6 or XELOX
15 Completed Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Neoplasms
Interventions: Drug: Paclitaxel;   Drug: EPO
16 Completed Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
Conditions: Chemotherapeutic Agent Toxicity;   Colorectal Cancer;   Neuropathy;   Neurotoxicity
Interventions: Drug: calcium gluconate;   Drug: magnesium sulfate;   Other: placebo;   Drug: oxaliplatin
17 Recruiting Impact of Adjuvant FOLFOX on Quality of Life and Sensory Neurotoxicity in Patients With Advanced Gastric Cancer
Condition: Stomach Neoplasms
Intervention: Other: Quality of life assessment
18 Completed Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
Conditions: Breast Neoplasms;   Breast Diseases;   Metastases, Neoplasm
Interventions: Drug: BNP7787;   Drug: Placebo
19 Completed Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
Conditions: Metastases;   Colorectal Neoplasms;   Colorectal Carcinoma
Interventions: Drug: Xaliproden (SR57746A);   Drug: Placebo;   Drug: Oxaliplatin;   Drug: 5-Fluorouracil;   Drug: Leucovorin
20 Completed XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy
Conditions: Metastases;   Colorectal Neoplasms;   Colorectal Carcinoma
Intervention: Drug: SR57746A

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.